AI identifies new product candidate for lupus
Charles River Laboratories and Valo Health have announced the identification of an advanceable product candidate for the treatment of different forms of lupus and other autoimmune indications.
The discovery was the first using Logica, an artificial intelligence (AI)-powered drug development solution that translates biological insights into optimised preclinical assets.
“Identification of this first lead candidate provides proof-of-concept for Logica as an engine to expedite and enhance drug discovery in a critical therapeutic area,” said Professor Julie Frearson, Senior Vice President and Chief Scientific Officer, Charles River. “Together with our partners at Valo Health and through our ongoing collaboration with Flagship’s Pioneering Medicines, we look forward to further leveraging the power of Logica to advance this program into lead optimisation.”
Logica, the result of a strategic partnership between Charles River and Valo Health, is the industry’s first computation-powered, unified target-to-candidate offering.
The Logica Advanceable Lead (Logica-AL) program integrates Valo’s DNA-encoded libraries and Opal Computational Platform with Charles River’s expertise in high-throughput screening to produce potent advanceable leads.
The Logica Candidate (Logica-C) platform was created to use those leads and trained predictive models to deliver a candidate that will ultimately be ready for IND-enabling studies.
“We entered our collaboration with Charles River and Valo with a shared goal of accelerating the drug discovery process, and of expediting the development of critically needed therapies for patients with limited or no treatment options,” said Luisa Salter-Cid, Chief Scientific Officer, Pioneering Medicines. “Logica’s early success in identifying a potential therapy for an autoimmune disease has built confidence in that shared goal, and we are excited to continue working with the team as our programme progresses.”
DIANA SPENCER, Senior Digital Content Editor, DDW
